1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Sophiris Targets Prostate Cancer With Modified Biologic

 
• By Mike Ward

Nearly 140,000 men each year are diagnosed with localized prostate cancer, and the common treatment is radical - surgical removal of the prostate or whole organ radiation. Sophiris Bio is a San Diego-based biotech developing topsalysin for the focal treatment of localized prostate cancer, and may spare the organ from such massive collateral damage. Speaking at the Biotech Showcase, Sophiris CEO Randall Woods explained to Scrip how topsalysin works and how he is looking to continue clinical development of the biologic, in both localized prostate cancer and benign prostatic hyperplasia.

Video interview

C#200400833:Sophiris Bio Inc.] is expecting 2018 to be a pivotal year for the company. It aims to unveil data relating to a Phase IIb trial of topsalysin in localized prostate cancer, complete preparation for a single Phase III registration trial for the indication, as well as look for support to develop the biologic as a treatment for benign prostatic hyperplasia, which has completed one Phase III trial.

While the company has funds to complete the Phase II trial it is looking for additional funds and partners to pursue a single Phase III registration trial in localized prostate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

More from Therapy Areas